Last reviewed · How we verify
Comparator: Placebo to ezetimibe/simvastatin — Competitive Intelligence Brief
phase 3
Combination lipid-lowering agent (ezetimibe + statin)
NPC1L1 transporter (ezetimibe); HMG-CoA reductase (simvastatin)
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Comparator: Placebo to ezetimibe/simvastatin (Comparator: Placebo to ezetimibe/simvastatin) — Organon and Co. Ezetimibe/simvastatin is a combination that reduces cholesterol by blocking intestinal cholesterol absorption (ezetimibe) and inhibiting hepatic cholesterol synthesis (simvastatin).
Comparator set (5 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Comparator: Placebo to ezetimibe/simvastatin TARGET | Comparator: Placebo to ezetimibe/simvastatin | Organon and Co | phase 3 | Combination lipid-lowering agent (ezetimibe + statin) | NPC1L1 transporter (ezetimibe); HMG-CoA reductase (simvastatin) | |
| Ezetimibe and Simvastatin | Ezetimibe and Simvastatin | University of Texas Southwestern Medical Center | marketed | Combination lipid-lowering agent (ezetimibe + statin) | NPC1L1 transporter (ezetimibe); HMG-CoA reductase (simvastatin) | |
| Ezetimibe + Simvastatin | Ezetimibe + Simvastatin | Organon and Co | marketed | Combination lipid-lowering agent (ezetimibe + statin) | NPC1L1 transporter (ezetimibe); HMG-CoA reductase (simvastatin) | |
| EZE/simvastatin | EZE/simvastatin | Azienda Ospedaliero Universitaria di Sassari | marketed | Combination lipid-lowering agent (ezetimibe + statin) | NPC1L1 transporter (ezetimibe); HMG-CoA reductase (simvastatin) | |
| ezetimibe/simvastatin 10/40 | ezetimibe/simvastatin 10/40 | Organon and Co | phase 3 | Combination lipid-lowering agent (ezetimibe + statin) | NPC1L1 transporter (ezetimibe); HMG-CoA reductase (simvastatin) | |
| Comparator: ezetimibe and simvastatin | Comparator: ezetimibe and simvastatin | Organon and Co | phase 3 | Combination lipid-lowering agent (ezetimibe + statin) | NPC1L1 transporter (ezetimibe) and HMG-CoA reductase (simvastatin) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Combination lipid-lowering agent (ezetimibe + statin) class)
- Organon and Co · 4 drugs in this class
- Azienda Ospedaliero Universitaria di Sassari · 1 drug in this class
- University of Texas Southwestern Medical Center · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Comparator: Placebo to ezetimibe/simvastatin CI watch — RSS
- Comparator: Placebo to ezetimibe/simvastatin CI watch — Atom
- Comparator: Placebo to ezetimibe/simvastatin CI watch — JSON
- Comparator: Placebo to ezetimibe/simvastatin alone — RSS
- Whole Combination lipid-lowering agent (ezetimibe + statin) class — RSS
Cite this brief
Drug Landscape (2026). Comparator: Placebo to ezetimibe/simvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/comparator-placebo-to-ezetimibe-simvastatin. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab